Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Novartis Unit Developing Denosumab For Osteoporosis

 
• By Dean Rudge
Businessmen_Leapfrog
Sandoz believes its biosimilar program is the most advanced globally • Source: Shutterstock

More from Biosimilars

More from Products